Clinigen Group

Clinigen Group is a rapidly-growing specialty pharmaceutical and services company with a unique business model dedicated to delivering the right drug to the right patient at the right time to improve the quality of people’s lives around the world. The Group consists of four synergistic businesses that provide medicines to patients with unmet need through clinical trials, licensed and unlicensed routes: Clinigen Clinical Trial Services (CTS) - The global leader in the specialist supply and management of quality-assured comparator drugs and other commercial medicines for patients in clinical trials. Cinigen is also the leading global patient access specialist working to provide ethical and compliant access to unlicensed medicines for healthcare providers and their patients with high unmet medical need: Idis Managed Access (MA) - Ethically manages early access to unlicensed investigational medicines on behalf of pharmaceutical and biotech companies. Idis Global Access (GA) - Enables access to post-approved medicines in regions where they are not commercially available but where there is a patient need. Clinigen Specialty Pharmaceuticals (SP) - Revitalizes essential hospital only medicines ensuring continuity of supply to hospital pharmacists, doctors and patients.
Burton upon Trent, GB
155 (est)

Clinigen Group Locations

Burton upon Trent, GB

Clinigen Group Metrics

Clinigen Group Summary

Founding Date


Market capitalization

£852 M

Closing share price


Clinigen Group Financials

FY, 2013FY, 2014FY, 2015


£123 M£127 M£184 M

Revenue growth, %


Gross profit

£35.1 M£41.2 M£53.7 M

Gross profit Margin, %


Operating expense total

£20.5 M£19.7 M£44.5 M

Clinigen Group Market Value History

Clinigen Group News

Clinigen Group Company Life